Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Recruiting now Phase 3 NCT07311850
Run by Pfizer · for 18 and older · All sexes
What this study is about
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Who can join (things the study team will check)
✅ You may be able to join if…
- BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to <30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
🚫 You may not be able to join if…
- Have any form of diabetes
- Have a self-reported body weight change > 5 kg (11 pounds) within 3 months prior to Screening
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease
Where this trial is running
- Headlands Research, Scottsdale, Arizona, United States
- Alliance Research Institute, Canoga Park, California, United States
- Collaborative Neuroscience Research, LLC, Garden Grove, California, United States
- Clinical Innovations, Inc dba CITrials, Riverside, California, United States
- Peninsula Headlands LLC, Rolling Hills, California, United States
- CenExcel Rocky Mountain Clinical Research, LLC, Englewood, Colorado, United States
- Research Centers of America, Hollywood, Florida, United States
- Future Medical Research (Civia Health), Longwood, Florida, United States
- Advanced Clinical Research, Miami, Florida, United States
- Oviedo Medical Research, Oviedo, Florida, United States
- CenExel FCR - ForCare Clinical Research, Tampa, Florida, United States
- DelRicht Research @ Springer Wellness and Restorative Health, Atlanta, Georgia, United States
+ 159 more sites.
Who to contact
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07311850.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.